Research Article
Characterization of Desmoglein 3 (DSG3) as a Sensitive and Specific Marker for Esophageal Squamous Cell Carcinoma
Table 4
DSG3 immunostaining in esophageal adenocarcinoma, small-cell lung carcinoma, and large B-cell lymphoma.
| | DSG3 proportion (average, range) | | Adenocarcinoma MD cases () | 2% (0-10%) | | Adenocarcinoma PD cases () | 2% (0-10%) | | Small-cell lung carcinoma () | 0% (0-0%) | | Large B-cell lymphoma () | 0% (0-0%) | | DSG3 proportion range () | | <5% | 5-25% | 26-50% | 51-75% | >75% | | Adenocarcinoma MD cases () | 6 | 1 | 0 | 0 | 0 | | Adenocarcinoma PD cases () | 12 | 3 | 0 | 0 | 0 | | DSG3 intensity (number) | | None | Weak | Strong | | Adenocarcinoma MD cases () | 4 | 3 | 0 | | Adenocarcinoma PD cases () | 10 | 5 | 0 | | Percentage of positive cases (≥5% immunoreactive cells) | | Adenocarcinoma MD cases () | 14% (1/7) | | Adenocarcinoma PD cases () | 20% (3/15) | | Adenocarcinoma, all cases () | 18% (4/22) | | Small-cell lung carcinoma () | 0% (0/20) | | Large B-cell lymphoma () | 0% (0/20) |
|
|
Abbreviations: MD: moderately differentiated; PD: poorly differentiated.
|
